BidaskClub downgraded shares of Becton, Dickinson and Company (NYSE:BDX) from a buy rating to a hold rating in a research note released on Sunday.

A number of other research firms also recently weighed in on BDX. Royal Bank Of Canada reaffirmed a hold rating and issued a $177.00 price target on shares of Becton, Dickinson and in a research note on Thursday, April 13th. Cowen and Company reaffirmed an outperform rating and issued a $230.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Evercore ISI raised shares of Becton, Dickinson and from an in-line rating to an outperform rating and upped their price target for the stock from $186.00 to $200.00 in a research note on Monday, April 24th. Zacks Investment Research raised shares of Becton, Dickinson and from a hold rating to a buy rating and set a $225.00 price target on the stock in a research note on Monday, July 17th. Finally, Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an outperform rating to a strong-buy rating and dropped their price target for the stock from $210.00 to $180.00 in a research note on Friday, June 30th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of Buy and an average price target of $194.69.

Becton, Dickinson and (NYSE:BDX) opened at 197.84 on Friday. Becton, Dickinson and has a 52-week low of $161.29 and a 52-week high of $206.63. The stock has a market cap of $42.20 billion, a P/E ratio of 32.86 and a beta of 1.05. The firm’s 50-day moving average price is $198.24 and its 200 day moving average price is $186.80.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. During the same period in the previous year, the business earned $2.35 EPS. The company’s revenue was down 5.1% on a year-over-year basis. Equities analysts predict that Becton, Dickinson and will post $9.45 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “BidaskClub Lowers Becton, Dickinson and Company (NYSE:BDX) to Hold” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/10/bidaskclub-lowers-becton-dickinson-and-company-nysebdx-to-hold.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a yield of 1.48%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

In related news, VP Jeffrey S. Sherman sold 28,765 shares of the company’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total value of $5,349,714.70. Following the completion of the sale, the vice president now directly owns 70,821 shares in the company, valued at $13,171,289.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.40% of the company’s stock.

Large investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Becton, Dickinson and by 5.3% in the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock worth $2,917,094,000 after buying an additional 796,034 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Becton, Dickinson and by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock worth $727,863,000 after buying an additional 242,081 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock worth $602,246,000 after buying an additional 39,362 shares in the last quarter. Finally, Fundsmith LLP boosted its stake in shares of Becton, Dickinson and by 3.2% in the first quarter. Fundsmith LLP now owns 2,296,613 shares of the medical instruments supplier’s stock worth $421,291,000 after buying an additional 71,691 shares in the last quarter. Hedge funds and other institutional investors own 75.71% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.